Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ERDAFITINIB for Plasma cell myeloma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 8 adverse event reports in the FDA FAERS database where ERDAFITINIB was used for Plasma cell myeloma.

Most Reported Side Effects for ERDAFITINIB

Side Effect Reports % Deaths Hosp.
Death 255 23.1% 255 8
Off label use 86 7.8% 5 16
Diarrhoea 75 6.8% 5 22
Stomatitis 58 5.2% 6 15
Fatigue 45 4.1% 4 13
Onycholysis 44 4.0% 8 15
Disease progression 41 3.7% 8 14
Dry mouth 41 3.7% 3 12
Nail disorder 40 3.6% 1 4
Hyperphosphataemia 39 3.5% 4 11
Dry eye 38 3.4% 4 3
Mucosal inflammation 35 3.2% 5 5
Decreased appetite 33 3.0% 4 17
Drug ineffective 33 3.0% 8 4
Nail discolouration 31 2.8% 1 11

Other Indications for ERDAFITINIB

Product used for unknown indication (641) Transitional cell carcinoma (168) Bladder cancer (74) Neoplasm (28) Cholangiocarcinoma (19) Metastatic carcinoma of the bladder (18) Transitional cell carcinoma metastatic (18) Breast cancer metastatic (13) Bladder transitional cell carcinoma (9) Urethral cancer (8)

Other Drugs Used for Plasma cell myeloma

LENALIDOMIDE (273,951) POMALIDOMIDE (81,096) DEXAMETHASONE (49,067) BORTEZOMIB (31,567) DARATUMUMAB (19,119) IXAZOMIB (17,602) CARFILZOMIB (15,333) THALIDOMIDE (10,689) CYCLOPHOSPHAMIDE (9,148) REVLIMID (7,122)

Related Pages

ERDAFITINIB Full Profile All Plasma cell myeloma Drugs ERDAFITINIB Demographics ERDAFITINIB Timeline